Pemetrexed Can Replace Carboplatin in Standard NSCLC Therapy, Small Phase 2 Study Suggests

Share this content:
Pemetrexed can replace platinum compounds such as carboplatin in first-line standard therapy for NSCLC.
Pemetrexed can replace platinum compounds such as carboplatin in first-line standard therapy for NSCLC.

Pemetrexed can replace platinum compounds such as carboplatin in first-line standard therapy for stage 3b and 4 non-small cell lung cancer (NSCLC), according to a recent study published in The Oncologist.

In a phase 2 study, Gunnar Hillerdal, MD, PhD, of the Karolinska Hospital in Sweden and colleagues randomized patients with NSCLC, with 50 who underwent standard carboplatin plus gemcitabine therapy and 44 who underwent pemetrexed and gemcitabine.

RELATED: Aprepitant Not Superior to Metoclopramide in Preventing Cisplatin-Induced Emesis

They found that there were 16 partial responses in the pemetrexed group, and 10 in the carboplatin group.

Additionally, patients treated with pemetrexed had a mean survival of 15 months compared to 9 months with carboplatin, with similar side effects in both.

“A trend toward better survival was observed in the patients receiving pemetrexed instead of a platinum compound, and this should be studied further,” the authors concluded.

Editor's Note: The original headline of this article stating that pemetrexed can replace carboplatin in non-small cell lung cancer was misleading. Although the study produced promising results, it was a small phase II trial that needs larger scale confirmation before changes to practice should be considered.

Reference

  1. Branden, Eva, et al. "Pemetrexed and Gemcitabine Versus Carboplatin and Gemcitabine in Non-Small Cell Lung Cancer: A Randomized Noninferiority Phase II Study in One Center." The Oncologist. doi: 10.1634/theoncologist.2014-0181. [epub ahead of print]. March 2, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters